112433-51-9

Usage

General Description

2-FLUORO-1,1-DIMETHYL-ETHYLAMINE HCL-SALT is a chemical compound that consists of the salt form of the amine 2-fluoro-1,1-dimethyl-ethylamine. It is a derivative of ethylamine that contains a fluorine atom attached to the carbon backbone. 2-FLUORO-1,1-DIMETHYL-ETHYLAMINE HCL-SALT is commonly used in organic synthesis and pharmaceutical research as a building block or intermediate in the production of various chemicals and pharmaceuticals. Its properties and structure make it a versatile and useful reagent in the field of organic chemistry.

InChI:InChI=1/C4H10FN.ClH/c1-4(2,6)3-5;/h3,6H2,1-2H3;1H

Upstream product

• 228547-65-7 N-benzyl-2-amino-1-fluoro-2-methylpropane 
• 228547-67-9 N-benzyl-N-(2-fluoro-1,1-dimethyl-ethyl)-hydroxylamine 
• 130436-05-4 2-fluoro-1,1-dimethylethylamine-N-carboxaldehyde 

Downstream Products

• 223444-59-5 N-(2-Fluoro-1,1-dimethylethyl)-2,4-difluorobenzamide 
• 130435-34-6 3-(2-chloro-4,5-difluorophenyl)-3-oxo-2-<<(1,1-dimethyl-2-fluoroethyl)amino>methylene>propanoic acid ethyl ester 

Relevant academic research and scientific papers

1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE

The present invention relates to a compound represented by Formula (I): wherein Ar1, Ar2, R1 and R2 each represent a substituent, a salt thereof, or a solvate of the compound or the salt, and to a medicine containing the same. According to the present invention, a potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.

AMIDOPYRAZOLE DERIVATIVE

A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.

Improved syntheses of fluorinated tertiary butylamines

Two new and efficient methods using cyclic sulfamidate and nitrone chemistry were developed for the synthesis of the sterically congested 1,1- dimethyl-2-fluoroethylamine (1), 2-fluoro-1-(fluoromethyl)-1-methylethylamine (2) and 2-fluoro-1,1-bis-(fluoromethyl)-ethylamine (3).

Fluorinated tertiary butylamines

New fluorinated tertiary butylamines of the formula STR1 are prepared from halogenated pivalic acid halides by a reaction sequence which comprises preparing the fluorinated pivalic acid and decomposition of the azide to the corresponding isocyanate. The isocyanate can be converted to the fluorinated tertiary butylamine acid addition salt by acid hydrolysis or directly to the amine by treatment with base. In addition, the present amines can be prepared by reaction of a pivalic acid amide with hypochlorite. The new butylamines can be used in the preparation of benzoic acid amides having insecticidal action.

Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri

A series of novel N-1-(mono-, -(di- and -(trifluoro-tert-butyl) quinolones and -naphthyridines has been prepared. Structure-activity relationship (SAR) studies indicated that the in vitro antibacterial potency was the following order: 1-(1,1-dimethyl-2-fl